Primary Immune Deficiency (PID) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Primary Immune Deficiency (PID) Marketed and Pipeline Drugs Overview

PIDs, also known as inborn errors of immunity (IEI), are a group of more than 400 rare, chronic conditions. In this part of the body’s immune system is either missing or does not function correctly. Any component of the immune system—cells, proteins (immunoglobulins), enzymes involved in immune regulation—may be at defect causing PID. These conditions are caused by hereditary genetic defects and can affect anyone, regardless of age, gender, or ethnicity.

The Primary Immune Deficiency (PID) marketed and pipeline drugs market research report includes an assessment of the disease epidemiology, leading marketed products with sales forecast, pricing and reimbursement, and late-to-mid-stage pipeline products with Phase Transition Success Rate (PTSR), and Likelihood of Approval (LoA) for Primary Immune Deficiency (PID). The report also analyzes the clinical and commercial landscapes of PID drugs, as well as an assessment of deals, future market catalysts, key market players, and the future competitive environment.

PID Marketed Drugs Segmentation by Mechanisms of Action

The key mechanisms of action in PID marketed drugs are enzyme inhibitor, enzyme activator, and enzyme replacement. In 2023, all MoAs have an equal number of marketed drugs.

PID Marketed Drugs Analysis by Mechanisms of Action, 2023 (%)

For More MoA Insights into PID Marketed Drugs Buy Full report, Download A Free Report Sample

PID Marketed Drugs Segmentation by Molecule Types

The key molecule types for PID marketed drugs are biologic and small molecule. In 2023, the majority of marketed drugs for PID are biologic therapies.

PID Marketed Drugs Analysis by Molecule Types, 2023 (%)

For More Molecule Types Insights into PID Marketed Drugs Buy Full report, Download A Free Report Sample

PID Marketed Drugs Segmentation by Routes of Administration

The key routes of administration for PID marketed drugs are injection and oral. In 2023, most of the marketed drugs available for PID are injectable.

PID Marketed Drugs Analysis by Routes of Administration, 2023 (%)

For More RoA Insights into PID Marketed Drugs Buy Full report, Download A Free Report Sample

PID Pipeline Drugs Market Segmentation by Mechanisms of Action

The key mechanisms of action for PID pipeline drugs are enzyme activator, receptor antagonist, receptor agonist, enzyme inhibitor, and protein and peptide activator among others. In 2023, most of the pipeline drugs in the PID landscape are enzyme activators.

PID Pipeline Drugs Market Analysis by Mechanisms of Action, 2023 (%)

 For More MoA Insights into The PID Pipeline Drugs Market Buy Full report, Download A Free Report Sample

PID Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration for PID pipeline drugs are oral, injection, and topical. In 2023, most pipeline drugs for PID are injection therapies followed by oral drugs.

PID Pipeline Drugs Market Analysis by Routes of Administration, 2023 (%)

For More RoA Insights into The PID Pipeline Drugs Market Buy Full report, Download A Free Report Sample

PID Pipeline Drugs Market Segmentation by Molecule Type

The key molecule types for the PID pipeline drugs market are biologic, small molecule, and oligonucleotide. In 2023, most of the pipeline drugs in the PID drug development landscape are biologics.

PID Pipeline Drugs Market Analysis by Molecule Types, 2023 (%)

For More Molecule Type Insights into The PID Pipeline Drugs Market Buy Full report, Download A Free Report Sample

Top Sponsors in the PID Marketed and Pipeline Drugs Market

Some of the top sponsors in the PID marketed and pipeline drugs market are Octapharma AG, Grifols SA, CSL Ltd, UCB SA, and Kedrion Spa among others. The majority of the completed trials conducted in the PID space over the past 10 years were sponsored by pharma companies, led by Octapharma, and followed by Grifols.

PID Marketed and Pipeline Drugs Segments

PID Marketed Drugs Mechanism of Action (Number of Drugs, 2023)

• Enzyme Inhibitor
• Enzyme Activator
• Enzyme Replacement

PID Marketed Drugs Molecule Types Outlook (Number of Drugs, 2023)

• Biologic
• Small Molecule

PID Marketed Drugs Routes of Administration Outlook (Number of Drugs, 2023)

• Oral
• Injection

PID Pipeline Drugs Mechanisms of Action Outlook (Number of Drugs, 2023)

• Enzyme Activator
• Receptor Antagonist
• Receptor Agonist
• Enzyme Inhibitor
• Protein and Peptide Activator

PID Pipeline Drugs Routes of Administration Outlook (Number of Drugs, 2023)

• Oral
• Injection
• Topical

PID Pipeline Drugs Molecule Types Outlook (Number of Drugs, 2023)

• Small Molecule
• Biologic

Scope

GlobalData’s PID: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include –

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the PID market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global PID market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.